Library

Library

Scientific

HFB200301

American Society of Clinical Oncology | April 27, 2022

Phase I study of HFB200301, a First-in-Class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS™) Phase I study of HFB200301, a First-in-Class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS™)

Poster
American Association for Cancer Research | April 12, 2021

Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer

Publication
American Association for Cancer Research | July 03, 2020

Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment

Poster

HFB301001

European Society for Medical Oncology Congress | September 12, 2022

Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS™) Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS™)

Poster
American Association for Cancer Research | April 12, 2021

Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody

Publication
American Association for Cancer Research | July 03, 2020

HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy

Poster

HFB200603

American Association for Cancer Research | April 13, 2022

HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment

Poster

HFB200902

American Association for Cancer Research | April 12, 2021

HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers

Publication
Nature Scientific | March 04, 2021

Serial transplantation unmasks galectin‐9 contribution to tumor immune escape in the MB49 murine model Serial transplantation unmasks galectin‐9 contribution to tumor immune escape in the MB49 murine model

Publication
American Association for Cancer Research | July 03, 2020

HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment

Poster

HFB101110

American Association for Cancer Research | April 18, 2022

Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors

Poster

HFB100204

American Association for Cancer Research | April 12, 2021

Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas

Publication

Platform

American Association for Cancer Research | April 08, 2022

Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization

Poster
Science Advances | June 11, 2021

High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics

Publication
American Association for Cancer Research | September 17, 2020

HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS™ Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference

Publication
Nature Biotechnology | March 30, 2020

High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics

Publication
Nature Genetics | May 31, 2019

High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer

Publication
Nature Biotechnology | September 11, 2017

Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring

Publication
HiFiBio, Paris | November 13, 2016

Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study

Poster

Strategy

Innovative Drug Discovery

Drug Discovery Today | May 2023

Global or local: The future of biotech Global or local: The future of biotech

Publication
Drug Discovery Today | October 2017

Guiding principles of value creation through collaborative innovation in pharmaceutical research Guiding principles of value creation through collaborative innovation in pharmaceutical research

Publication